Literature DB >> 6104085

Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C.

B G Jones, J W Fielding, C E Newman, A Howell, V S Brookes.   

Abstract

In a multicentre trial of adjuvant chemotherapy in gastric adenocarcinoma, a number of patients developed chronic haemolysis and renal failure following long-term treatment with 5-fluorouracil and mitomycin-C. This was exacerbated by blood transfusion, leading to an acute intravascular haemolytic state accompanied by rapid decline in renal function. One patient investigated extensively was treated with antiplatelet drugs, steroids, and fresh frozen plasma without success. At necropsy this patient and another had renal changes typical of the haemolytic-uraemic syndrome and no evidence of tumour recurrence. Long-term treatment with this drug combination is potentially dangerous, and routine monitoring of renal function is recommended.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104085     DOI: 10.1016/s0140-6736(80)91734-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Edward C Gordon-Smith; Andrew M Pilling; Kai Chiu Liu; Sian Rizzo; Susan Sulsh; John A Turton
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment.

Authors:  G Agnelli; P Gresele; G G Nenci
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Nonspecific and selective stimulation of the immune system in the treatment of carcinoma in humans.

Authors:  R E Falk; L Makowka; U Ambus; J A Falk; R Bugala; S Landi
Journal:  Can Med Assoc J       Date:  1983-06-15       Impact factor: 8.262

4.  Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat.

Authors:  V Cattell
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

5.  Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.

Authors:  J van der Meer; E G de Vries; R Vriesendorp; P H Willemse; A J Donker; J G Aalders
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group.

Authors:  J W Fielding; S L Fagg; B G Jones; D Ellis; M S Hockey; A Minawa; V S Brookes; J L Craven; M C Mason; A Timothy; J A Waterhouse; P F Wrigley
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

7.  Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations.

Authors:  S E Zimmerman; F P Smith; T M Phillips; R J Coffey; P S Schein
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-15

8.  Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.

Authors:  J Crocker; E L Jones
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

Review 9.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.